PMID- 33145091
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201106
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep
TI  - Role of theranostics in thoracic oncology.
PG  - 5140-5146
LID - 10.21037/jtd-2019-pitd-13 [doi]
AB  - Theranostics is a re-emerging field of medicine that aims to create targeted 
      agents that can be used for diagnostic and/or therapeutic indications. In the 
      past, theranostics has been used to treat neoplasms, such as thyroid cancer and 
      neuroblastomas. More recently, theranostics has seen a resurgence with advent of 
      new therapeutic antibodies and small molecules which can be transformed into 
      Theranostic agents through radioconjugating with a radioactive isotope. Positron 
      emitting radioisotopes can be used for diagnostic purposes while alpha- and 
      beta-emitting radioisotopes can be used for therapy. The technique of 
      radiolabeling an existing therapeutic agent (small molecule or antibody) 
      leverages the existing qualities of that drug, and potentiates therapeutic effect 
      by conjugating it with a cytotoxic-energy bearing radioisotope (e.g., 131-iodine, 
      177-lutetium). Theranostics have been used for a few decades now, starting with 
      131-iodine for therapy of autoimmune thyroiditis (Graves' disease, Hashimoto's 
      thyroiditis) as well as for thyroid cancer. Additionally, 
      131-iodine-meta-iodobenzylguanidine (131-I-MIBG) initially had been used for 
      gastroenteropancreatic neuroendocrine (carcinoid) tumors. However, recently 
      clinical trials have start enrolling patients to evaluate efficacy of 131-I-MIBG 
      in patients with small cell carcinoma of the lung. In the era of precision 
      medicine and personalized targeted therapeutics, Theranostics can play a key 
      pivotal in improving diagnostic and therapeutic specificity by increasing potency 
      of these targeted small molecules and antibodies with radioisotopes. In this 
      review, we will review various clinically relevant Theranostics agent and their 
      utility in thoracic disorders, notably within oncology.
CI  - 2020 Journal of Thoracic Disease. All rights reserved.
FAU - Filippov, Aleksandr
AU  - Filippov A
AD  - Department of Diagnostic and Interventional Radiology, City of Hope National 
      Medical Center, Duarte, CA, USA.
FAU - Bonjoc, Kimberley-Jane C
AU  - Bonjoc KC
AD  - Department of Diagnostic and Interventional Radiology, City of Hope National 
      Medical Center, Duarte, CA, USA.
FAU - Chea, Junie
AU  - Chea J
AD  - Department of Diagnostic and Interventional Radiology, City of Hope National 
      Medical Center, Duarte, CA, USA.
FAU - Bowles, Nicole
AU  - Bowles N
AD  - Department of Diagnostic and Interventional Radiology, City of Hope National 
      Medical Center, Duarte, CA, USA.
FAU - Poku, Erasmus
AU  - Poku E
AD  - Department of Diagnostic and Interventional Radiology, City of Hope National 
      Medical Center, Duarte, CA, USA.
FAU - Chaudhry, Ammar
AU  - Chaudhry A
AD  - Department of Diagnostic and Interventional Radiology, City of Hope National 
      Medical Center, Duarte, CA, USA.
LA  - eng
GR  - K12 CA001727/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC7578517
OTO - NOTNLM
OT  - AXL
OT  - CAR T
OT  - FDG
OT  - FET
OT  - FLT
OT  - PSMA
OT  - Theranostics
OT  - lung metastasis
OT  - lymphoma
OT  - mIBG
OT  - neuroendocrine tumors
OT  - non-small cell lung cancer (NSCLC)
OT  - nuclear medicine
OT  - positron emission tomography (PET)
OT  - small cell lung cancer (SCLC)
OT  - thoracic adenopathy
OT  - thymoma
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at: http://dx.doi.org/10.21037/jtd-2019-pitd-13). The series 
      "Role of Precision Imaging in Thoracic Disease" was commissioned by the editorial 
      office without any funding or sponsorship. AC served as an unpaid Guest Editor of 
      the series. The other authors have no other conflicts of interest to declare.
EDAT- 2020/11/05 06:00
MHDA- 2020/11/05 06:01
PMCR- 2020/09/01
CRDT- 2020/11/04 05:44
PHST- 2020/11/04 05:44 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/05 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - jtd-12-09-5140 [pii]
AID - 10.21037/jtd-2019-pitd-13 [doi]
PST - ppublish
SO  - J Thorac Dis. 2020 Sep;12(9):5140-5146. doi: 10.21037/jtd-2019-pitd-13.